よむ、つかう、まなぶ。
会議資料 (155 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00042.html |
| 出典情報 | 医薬・生活衛生局が実施する検討会 医療上の必要性の高い未承認薬・適応外薬検討会議（第68回 7／4）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
（公知申請への該当性に係る企業見解の様式）
要望番号；IV-169
the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol
2013; 163(1): 118-122.
29) Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety
profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.
Haematologica 2007; 92(12): 1695-1698.
30) Berentsen S, Tjønnfjord GE, Brudevold R, et al. Favourable response to therapy with the
anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J
Haematol 2001; 115(1): 79-83.
31) Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin
disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103(8):
2925-2928.
32) Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a
prospective study of 20 patients. Leuk Lymphoma 2006; 47(2): 253-260.
33) NHS England. Clinical Commissioning Policy: Rituximab for cytopaenia complicating primary
immunodeficiency. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/07/
Rituximab-for-cytopaenia-complicating-primary-immunodeficiency.pdf [Cited 2024 Apr 23]
34) Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial
evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults
(the RAIHA study). Am J Hematol 2017; 92(1): 23-27.
35) Dierickx D, Verhoef G, Hoof AV, et al. Rituximab in auto-immune haemolytic anaemia and
immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med
2009; 266(5): 484-491.
36) Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune
hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev 2015; 14(4): 304-313.
37) Cavallaro F, Barcellini W, Fattizzo B. Antibody based therapeutics for autoimmune hemolytic
anemia. Expert Opin Biol Ther 2023; 23(12): 1227-1237.
38) Cvetković Z, Pantić N, Cvetković M, et al. The Role of the Spleen and the Place of Splenectomy
in Autoimmune Hemolytic Anemia-A Review of Current Knowledge. Diagnostics (Basel). 2023;
13(18): 2891.
39) Bortolotti M, Barcellini W, Fattizzo B. Molecular pharmacology in complement-mediated
hemolytic disorders. Eur J Haematol 2023; 111(3): 326-336.
40) Berentsen S, Fattizzo B, Barcellini W. The choice of new treatments in autoimmune hemolytic
anemia: how to pick from the basket? Front Immunol 2023; 14:1180509.
41) Gelbenegger G, Berentsen S, Jilma B. Monoclonal antibodies for treatment of cold agglutinin
disease. Expert Opin Biol Ther 2023; 23(5): 395-406.
42) Goldman-Cecil medicine 27th ed volume 1. pp1087-1092.
43) Harrison's Principles of Internal Medicine 21st ed. pp786-788.
57
155 / 359
要望番号；IV-169
the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol
2013; 163(1): 118-122.
29) Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety
profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults.
Haematologica 2007; 92(12): 1695-1698.
30) Berentsen S, Tjønnfjord GE, Brudevold R, et al. Favourable response to therapy with the
anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J
Haematol 2001; 115(1): 79-83.
31) Berentsen S, Ulvestad E, Gjertsen BT, et al. Rituximab for primary chronic cold agglutinin
disease: a prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103(8):
2925-2928.
32) Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a
prospective study of 20 patients. Leuk Lymphoma 2006; 47(2): 253-260.
33) NHS England. Clinical Commissioning Policy: Rituximab for cytopaenia complicating primary
immunodeficiency. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/07/
Rituximab-for-cytopaenia-complicating-primary-immunodeficiency.pdf [Cited 2024 Apr 23]
34) Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial
evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults
(the RAIHA study). Am J Hematol 2017; 92(1): 23-27.
35) Dierickx D, Verhoef G, Hoof AV, et al. Rituximab in auto-immune haemolytic anaemia and
immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med
2009; 266(5): 484-491.
36) Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune
hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev 2015; 14(4): 304-313.
37) Cavallaro F, Barcellini W, Fattizzo B. Antibody based therapeutics for autoimmune hemolytic
anemia. Expert Opin Biol Ther 2023; 23(12): 1227-1237.
38) Cvetković Z, Pantić N, Cvetković M, et al. The Role of the Spleen and the Place of Splenectomy
in Autoimmune Hemolytic Anemia-A Review of Current Knowledge. Diagnostics (Basel). 2023;
13(18): 2891.
39) Bortolotti M, Barcellini W, Fattizzo B. Molecular pharmacology in complement-mediated
hemolytic disorders. Eur J Haematol 2023; 111(3): 326-336.
40) Berentsen S, Fattizzo B, Barcellini W. The choice of new treatments in autoimmune hemolytic
anemia: how to pick from the basket? Front Immunol 2023; 14:1180509.
41) Gelbenegger G, Berentsen S, Jilma B. Monoclonal antibodies for treatment of cold agglutinin
disease. Expert Opin Biol Ther 2023; 23(5): 395-406.
42) Goldman-Cecil medicine 27th ed volume 1. pp1087-1092.
43) Harrison's Principles of Internal Medicine 21st ed. pp786-788.
57
155 / 359